It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Thirteen years ago, a group of U.S. public health officials came up with a plan to address what they regarded as one of the medical system’s crucial vulnerabilities: a shortage of ventilators.
And then things suddenly veered off course. A multibillion-dollar maker of medical devices bought the small California company that had been hired to design the new machines. The project ultimately produced zero ventilators.
The stalled efforts to create a new class of cheap, easy-to-use ventilators highlight the perils of outsourcing projects with critical public-health implications to private companies; their focus on maximizing profits is not always consistent with the government’s goal of preparing for a future crisis.
…the Biomedical Advanced Research and Development Authority, with a mandate to prepare medical responses to chemical, biological and nuclear attacks, as well as infectious diseases. …. It estimated that an additional 70,000 machines would be required in a moderate influenza pandemic.
The ventilators were to cost less than $3,000 each.
Ventilators at the time typically went for about $10,000 each, and getting the price down to $3,000 would be tough. But Newport’s executives bet they would be able to make up for any losses by selling the ventilators around the world. … With luck, the new generation of ventilators would become ubiquitous, helping hospitals nationwide better prepare for a crisis.
Government officials and executives at rival ventilator companies said they suspected that Covidien had acquired Newport to prevent it from building a cheaper product that would undermine Covidien’s profits from its existing ventilator business.
Last week, the Health and Human Services Department contacted ventilator makers to see how soon they could produce thousands of machines. And it began pressing Philips to speed up its planned shipments.
The stockpile is “still awaiting delivery of the Trilogy Evo,” a Health and Human Services spokeswoman said. “We do not currently have any in inventory, though we are expecting them soon.”
originally posted by: FlyingSquirrel
a reply to: FyreByrd
The suspect company that foiled the ventilators from being made is named Covidien too.
You can't make this stuff up because it'd sound too obvious and corny.
originally posted by: odzeandennz
originally posted by: Lumenari
a reply to: FyreByrd
You stating that the New York Times is a reputable outlet made me skip the rest of your OP.
I'm assuming capitalism bad, socialism good?
You're just a mental case jebus... Ffs... Wtf are you talking about
originally posted by: TerryMcGuire
a reply to: FyreByrd
Fine thread Mr. Byrd. However, upon opening the thread, the first thing I saw was the link and the first thought that passed through my head was I wonder how long it will take for someone to discount the whole of the information you posted. Not long at all, hey what?
For the last month, Army reservist Lt. Col. Kamal Kalsi, an emergency room doctor in New York, has been scrambling to find a way to quickly mass produce ventilators, equipment that could save the lives of thousands of coronavirus victims nationwide.
Two weeks ago, he thought he’d found a company in Sacramento with the perfect answer.
But then, as he tells it, necessity took a back seat to business.
The firm Kalsi contacted wanted tens of millions of dollars before it would help him,
“This just needs to happen,” said Kalsi, a disaster medicine specialist who ran triage hospitals in Afghanistan.
“If we don’t get ventilators in the next week or two in New York, it’s going to be a bloodbath.”
The ventilator Kalsi sees as the solution is the Go2Vent, made by Vortran Medical in Sacramento and sold for about $100 each, though there is no proof it could be the panacea that he envisions.
Vortran’s founder and chief medical officer, Dr. Gordon Wong, declined to comment, other than to say Friday he was close to inking a mass production deal with a venture capital-backed manufacturer in Chicago.
Considering the source is part of critical thinking.
Even you knew that when you saw the source.
But yea... I'm the bad person in this scenario.
originally posted by: Lumenari
a reply to: FyreByrd
You stating that the New York Times is a reputable outlet made me skip the rest of your OP.
I'm assuming capitalism bad, socialism good?